42ND CONGRESS OF THE ESCRS
BARCELONA
6-10 SEPTEMBER 2024
Fira de Barcelona, Spain

GLAUKOS SPEAKERS CORNER

ESCRS 2024

SPEAKERS PROGRAM

You don't want to miss this!

Join our Expert Panel and learn about iStent *inject*® W, a **PROVEN SAFE** technology for an early intervention preserving Patients' Functional Vision[1] and Quality of Life[2]

GLAUKOS BOOTH
D56, Hall 7

SATURDAY SEPT. 7th

11:00 **Safety First: Optimizing Surgical Order for Glaucoma Treatment**
Florian Rüfer

12:30 **The Test of Time: Long-term Data Proves Safety and Efficacy**
Fritz Hengerer

14:00 **Reducing surgical Risks: The Impact of iStent *inject*® on Trabeculectomies**
Laura Morales

15:00 **Proven Over Time: iStent®'s Long-Term Safety and Efficacy**
Tobias Neuhann

SUNDAY SEPT. 8th

10:45 **The Glaucoma Surgical Journey: Prioritizing Safety with iStent *inject*® W**
José Mª Martínez de la Casa

11:15 **Interventional Glaucoma: Beyond Understanding to Action**
Ike Ahmed

13:00 **Interventional Glaucoma: Acting Early to Save Vision**
Anselm Jünemann

15:00 **Less Risk: Glaucoma Management with iStent *inject*® W**
Ana Miguel

GLAUKOS

1- Gillmann K, Hombeak DM. BMJ Open Ophth 2024;9:e001575.doi:10.1136/bmjophth-2023-001575.
2- Samuelson, Thomas W., et al. "Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent *inject*® pivotal trial." American Journal of Ophthalmology 229 (2021): 220-229.

iStent *inject*® W IMPORTANT SAFETY INFORMATION
INDICATION FOR USE: The iStent *inject* W, is intended to reduce intraocular pressure safely and effectively in patients diagnosed with primary open-angle glaucoma, pseudo-exfoliative glaucoma or pigmentary glaucoma. The iStent *inject* W, can deliver two (2) stents on a single pass, through a single incision. The implant is designed to stent open a passage through the trabecular meshwork to allow for an increase in the facility of outflow and a subsequent reduction in intraocular pressure. The device is safe and effective when implanted in combination with cataract surgery in those subjects who require intraocular pressure reduction and/or would benefit from glaucoma medication reduction. The device may also be implanted in patients who continue to have elevated intraocular pressure despite prior treatment with glaucoma medications and conventional glaucoma surgery. CONTRAINDICATIONS: The iStent *inject* W System is contraindicated under the following circumstances or conditions: • In eyes with primary angle closure glaucoma, or secondary angle-closure glaucoma, including neovascular glaucoma, because the device would not be expected to work in such situations. • In patients with retrobulbar tumor, thyroid eye disease, Sturge- Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. WARNINGS/ PRECAUTIONS: • For prescription use only. • This device has not been studied in patients with uveitic glaucoma. • Do not use the device if the Tyvek® lid has been opened or the packaging appears damaged. In such cases, the sterility of the device may be compromised. • Due to the sharpness of certain injector components (i.e. the insertion sleeve and trocar), care should be exercised to grasp the injector body. Dispose of device in a sharps container. • iStent *inject* W is MR-Conditional; see MRI Information below. • Physician training is required prior to use of the iStent *inject* W System. • Do not re-use the stent(s) or injector, as this may result in infection and/or intraocular inflammation, as well as occurrence of potential postoperative adverse events as shown below under "Potential Complications." • There are no known compatibility issues with the iStent *inject* W and other intraoperative devices. (e.g., viscoelastics) or glaucoma medications. • Unused product & packaging may be disposed of in accordance with facility procedures. Implanted medical devices and contaminated products must be disposed of as medical waste. • The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. If intraocular pressure is not adequately maintained after surgery, the surgeon should consider an appropriate treatment regimen to reduce intraocular pressure. • Patients should be informed that placement of the stents, without concomitant cataract surgery in phakic patients, can enhance the formation or progression of cataract. ADVERSE EVENTS: Please refer to Directions For Use for additional adverse event information. CAUTION: Please reference the Directions For Use labelling for a complete list of contraindications, warnings and adverse events.